Actively Recruiting
Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
Led by Advenchen Pharmaceuticals, LLC. · Updated on 2026-05-08
80
Participants Needed
7
Research Sites
317 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This trial is a Phase II trial designed to evaluate the safety and efficacy of using oral AL8326 , a multi-targeted receptor Tyrosine Kinase Inhibitor( TKI) , to recurrent, advanced, or metastatic small cell lung cancer (SCLC) patients , Non-Small Cell Lung (NSCLC) and Renal Cell Carcinoma patients who need ≥2nd line treatment .
CONDITIONS
Official Title
Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female, 18 years of age or older
- ECOG performance status of 0 or 1
- Histologically or cytologically confirmed small cell lung cancer, non-small cell lung cancer, or renal cell carcinoma
- At least one measurable lesion according to RECIST 1.1 criteria
- Life expectancy of at least 3 months
You will not qualify if you...
- Serious, non-healing wound, ulcer, or bone fracture
- Major surgery within 28 days or minor surgery within 7 days before treatment
- Active bleeding or high risk of bleeding conditions like bleeding disorders or tumors involving major vessels
- Significant cardiovascular disease including uncontrolled hypertension, recent heart attack or unstable angina within 6 months, severe heart failure, serious arrhythmia needing medication, or severe peripheral vascular disease
- Hemoptysis within 3 months before enrollment
- Use of strong CYP3A4, CYP2C9, or CYP2C19 inhibitors or inducers within 14 days before enrollment and during the study unless medically necessary
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
Actively Recruiting
2
Cleveland Clinic Florida
Weston, Florida, United States, 33331
Withdrawn
3
Northwestern University
Chicago, Illinois, United States, 60611
Completed
4
Siteman Cancer Center, Washington University
St Louis, Missouri, United States, 63130
Actively Recruiting
5
Cleveland Clinic
Cleveland, Ohio, United States, 44195
Actively Recruiting
6
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Actively Recruiting
7
Hospital Universitario Ramón Y Cajal
Madrid, Spain
Actively Recruiting
Research Team
S
Shiying Sprinzl
CONTACT
J
Judy Chen
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here